Abstracts tagged "outcomes"

Abstract Number: 2608 • 2017 ACR/ARHP Annual Meeting
Tacrolimus in Non-Asian Systemic Lupus Erythematosus Patients: A Real-Life Experience from Three European Centers
Chiara Tani¹, Miguel Martin-Cascon², Mériem Belhocine³, Roberta Vagelli¹, Chiara Stagnaro⁴, Guillermo Ruiz-Irastorza⁵, Nathalie Costedoat-Chalumeau³ and Marta Mosca¹, ¹Rheumatology Unit, University of Pisa, Pisa, Italy, ²Autoimmune Diseases Research Unit, BioCruces, Hospital Universitario Cruces, Barakaldo, Spain, ³Service de médecine interne Pôle médecine, Hôpital Cochin, Centre de référence maladies auto-immunes et systémiques rares de l’île de France, Paris, France, ⁴Rheumatology Unit, University of Pisa, PISA, Italy, ⁵Autoimmune Diseases Research Unit, BioCruces, Hospital Universitario Cruces, Baracaldo, Spain
Background/Purpose: there is no consensus on the use of Tacrolimus (TAC) in patients with SLE; clinical studies on TAC, including all the RCT, are mostly…
Abstract Number: 781 • 2017 ACR/ARHP Annual Meeting
A Patient Based Reliability Exercise of Omeract Ultrasound Definitions in Giant Cell Arteritis
Valentin S. Schäfer¹, Stavros Chrysidis², Christian Dejaco³, Christina Duftner⁴, Annamaria Iagnocco⁵, George A. W. Bruyn⁶, Greta Carrara⁷, MA D'Agostino⁸, Eugenio De Miguel⁹, Andreas P Diamantopoulos¹⁰, Ulrich Fredberg¹¹, Wolfgang Hartung¹², Alojzija Hočevar¹³, Tanaz A. Kermani¹⁴, Matthew J. Koster¹⁵, Tove Lorenzen¹⁶, Pierluigi Macchioni¹⁷, Marcin Milchert¹⁸, Uffe Møller Døhn¹⁹, Chetan Mukhtyar²⁰, Cristina Ponte²¹, Sofia Ramiro²², Carlo Alberto Scirè²³, Lene Terslev²⁴, Kenneth J. Warrington¹⁵, Bhaskar Dasgupta²⁵ and Wolfgang A. Schmidt²⁶, ¹Immanuel Krankenhaus Berlin, Medical Center for Rheumatology Berlin-Buch, Berlin, Germany, ²Department of Rheumatology, Hospital of Southwest Denmark, Esbjerg, Denmark, ³Rheumatology and Immunology, Medical University Graz, Graz, Austria, ⁴Department of Internal Medicine, Clinical Division of Internal Medicine II, Medical University Innsbruck, Innsbruck, Austria, ⁵Academic Rheumatology Unit, Università degli Studi di Torino, Torino, Italy, ⁶Rheumatology, MC Groep, Loenga, Netherlands, ⁷Epidemiology Unit, Italian Society for Rheumatology, Milano, Italy, ⁸Rheumatology, Versailles-Saint Quentin en Yvelines University, Boulogne-Billancourt, France, ⁹Medicine, Universidad Autonoma Madrid, MADRID, Spain, ¹⁰Martina Hansens Hospital, Bærum, Oslo, Norway, ¹¹Diagnostic Centre, Silkeborg Regional Hospital, 8600 Silkeborg, Denmark, ¹²Department of Rheumatology/Clinical Immunology, Asklepios Medical Center, 93077 Bad Abbach, Germany, ¹³Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia, ¹⁴Rheumatology, University of California Los Angeles, Los Angeles, CA, ¹⁵Rheumatology, Mayo Clinic, Rochester, MN, ¹⁶Diagnostic Centre, Region Hospital Silkeborg, Silkeborg, Denmark, ¹⁷Arcispedale Santa Maria Nuova, Reggio Emilia, Italy, ¹⁸Pomeranian Medical University, Szczecin,, Szczecin, Poland, ¹⁹Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Copenhagen Center for Arthritis Research (COPECARE), Glostrup, Denmark, ²⁰Norfolk and Norwich University Hospital, Norwich, United Kingdom, ²¹Rheumatology Department, Hospital de Santa Maria - Centro Hospital Lisboa Norte, Lisbon, Portugal, ²²Rheumatology, Department of Rheumatology, LUMC, Leiden, Netherlands, Leiden, Netherlands, ²³Italian Society for Rheumatology, Milan, Italy, ²⁴Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Denmark, Copenhagen, Denmark, ²⁵Rheumatology, Southend University Hospital NHS Foundation Trust, Southend, UK, Westcliff-on-Sea, United Kingdom, ²⁶Medical Center for Rheumatology and Clinical Immunology Berlin-Buch, Immanuel Krankenhaus Berlin, Berlin, Germany
Background/Purpose: To test the reliability of recently established consensus-based ultrasound definitions for normal and vasculitic temporal and axillary arteries in patients with giant cell arteritis…
Abstract Number: 2683 • 2017 ACR/ARHP Annual Meeting
Factors Associated with Disease Progression in Early-Diagnosed Pulmonary Arterial Hypertension Associated with Systemic Sclerosis
Carina Mihai¹, Milos Antic², Rucsandra Dobrota³, Diana Bonderman⁴, Harbajan Chadha-Boreham⁵, J. Gerry Coghlan⁶, Christopher Denton⁷, Martin Doelberg⁵, Ekkehard Gruenig⁸, Dinesh Khanna⁹, Vallerie McLaughlin¹⁰, Ulf Müller-Ladner¹¹, Janet E. Pope¹², Daniel M Rosenberg⁵, James R Seibold¹³, Madelon C Vonk¹⁴ and Oliver Distler¹⁵, ¹Internal Medicine and Rheumatology Dept., Cantacuzino Clinical Hospital, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania, ²University Hospital Zurich, Zurich, Switzerland, ³Department of Rheumatology, Center of Experimental Rheumatology, University Hospital Zurich, Zurich, Switzerland, ⁴Department of Internal Medicine II, Division of Cardiology, Medical University of Vienna, Vienna, Austria, ⁵Actelion Pharmaceuticals Ltd., Alschwil, Switzerland, ⁶National Pulmonary Hypertension Service, Royal Free Hospital, London, United Kingdom, ⁷Department of Rheumatology, University College London, Royal Free Hospital, London, United Kingdom, ⁸Centre for Pulmonary Hypertension, Thoraxclinic, University Hospital Heidelberg, Heidelberg, Germany, ⁹Division of Rheumatology and Clinical Autoimmune Center of Excellence, University of Michigan, Ann Arbor, MI, Ann Arbor, MI, ¹⁰Internal Medicine, Division of Cardiology, University of Michigan, Ann Arbor, MI, ¹¹Justus-Liebig-University Giessen, Department of Internal Medicine and Rheumatology, Kerckhoff-Klinik, Bad Nauheim, Germany, Bad-Nauheim, Germany, ¹²Department of Medicine, Division of Rheumatology, University of Western Ontario, St Joseph's Health Care, London, ON, Canada, ¹³Scleroderma Research Consultants LLC, Litchfield, CT, ¹⁴Rheumatology, Radboud University Medical Centre, Nijmegen, Netherlands, ¹⁵Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland
Background/Purpose: Pulmonary arterial hypertension (PAH) is a severe complication of systemic sclerosis (SSc), and its diagnosis requires right heart catheterization (RHC). The DETECT study developed…
Abstract Number: 923 • 2017 ACR/ARHP Annual Meeting
Can Education Mitigate the Effect of Poverty on Total Knee Replacement (TKR) Outcomes?
Susan M. Goodman¹, Bella Y. Mehta², Meng Zhang³, Jackie Szymonifka⁴, Iris Navarro-Millán⁵, Joseph T. Nguyen³, Yuo-Yu Lee³, Mark P. Figgie⁶, Michael L. Parks⁶, Shirin A. Dey⁴, Daisy Crego⁴, Linda A. Russell¹, Lisa A. Mandl¹ and Anne R. Bass¹, ¹Rheumatology, Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, ²Hospital for Special Surgery/Columbia University Mailman School of Public Health, New York, NY, ³Epidemiology and Biostatistics, Hospital for Special Surgery, New York, NY, ⁴Rheumatology, Hospital for Special Surgery, New York, NY, ⁵Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, ⁶Orthopaedic Surgery, Hospital for Special Surgery/Weill Cornell Medicine, New York, NY
Background/Purpose: Health outcomes after total knee replacement (TKR) are generally worse for patients from high poverty neighborhoods. Whether education mitigates the effect of poverty…
Abstract Number: 2848 • 2017 ACR/ARHP Annual Meeting
Improving Gout Outcomes: The Randomized Evaluation of an Ambulatory Care Pharmacist-Led Intervention to Optimize Urate Lowering Pathways (RAmP-Up) Study
Ted R. Mikuls¹, TC Cheetham², Gerald D. Levy³, Nazia Rashid⁴, Kimberly Low⁵, Brian W Coburn⁶, Kenneth Saag⁷, Lang Chen⁸ and Jeffrey R. Curtis⁹, ¹Internal Medicine, Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ²Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, ³Internal Medicine/Rheumatology, Kaiser Permanente Southern California, Downey, CA, ⁴Pharmacy Analytic Services, Kaiser Permanente Southern California, Downey, CA, ⁵Kaiser Permanente Southern California, Panorama City, CA, ⁶Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ⁷Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ⁸University of Alabama at Birmingham, Birmingham, AL, ⁹Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Allopurinol is a cornerstone therapy in gout management. Despite this, allopurinol use is suboptimal as providers often fail to follow the treat-to-target paradigm…
Abstract Number: 1288 • 2017 ACR/ARHP Annual Meeting
Renal Disease Course in Pediatric Anti-Neutrophil Cytoplasmic Antibody Associated Vasculitis in the First 12-Months – a Pediatric Vasculitis Initiative (PedVas) Study
Kimberly Morishita¹, Audrea Chen², Cherry Mammen¹, Angelyne Rivera³ and David Cabral¹, ¹BC Children's Hospital and University of British Columbia, Vancouver, BC, Canada, ²Medicine, University of British Columbia, Vancouver, BC, Canada, ³Pediatrics, BC Children's Hospital and University of British Columbia, Vancouver, BC, Canada
Background/Purpose: Renal disease is the most common manifestation of pediatric anti-neutrophil cycloplasmic antibody (ANCA) associated vasculitis (AAV). Renal disease course and early trajectories have not…
Abstract Number: 2864 • 2017 ACR/ARHP Annual Meeting
Anti-Acetylated Peptide Antibodies Positive Rheumatoid Arthritis Patients Show a More Favorable Response to Tumor-Necrosis-Factor Inhibitor Treatment and Better Disease Activity Control over Time
Paul Studenic¹, Stephan Blüml¹, Holger Bang², Daniela Sieghart¹, Daniel Aletaha¹, Helmuth Haslacher³, Josef S. Smolen^1,4 and Günter Steiner¹, ¹Medical University Vienna, Division of Rheumatology, Department of Internal Medicine III, Vienna, Austria, ²Orgentec Diagnostika GmbH, Mainz, Germany, ³Medical University Vienna, Department of Laboratory Medicine, Vienna, Austria, ⁴Department of Internal Medicine, Hietzing Hospital, Vienna, Austria
Background/Purpose: Anti-acetylated-peptide antibodies (AAPA) have been found in rheumatoid arthritis (RA) patients and may be additional markers for diagnosis, particularly in rheumatoid factor (RF)/ anti-citrullinated…
Abstract Number: 1299 • 2017 ACR/ARHP Annual Meeting
Patient-Reported Disease Activity and Adverse Pregnancy Outcomes in Systemic Lupus Erythematosus and Rheumatoid Arthritis
Nathaniel Harris¹, Amanda M. Eudy² and Megan E. B. Clowse², ¹Duke University School of Medicine, Durham, NC, ²Division of Rheumatology, Department of Medicine, Duke University Medical Center, Durham, NC
Background/Purpose: Patient-reported measures of disease activity may provide useful adjuncts to physician-reported measures in identifying pregnancies at greater risk for adverse pregnancy outcomes. Little is…
Abstract Number: 1317 • 2017 ACR/ARHP Annual Meeting
Obstetric Outcomes in Women with Rheumatoid Arthritis: Results from Nationwide Inpatient Sample Database 2003-2011
Shweta Kishore¹, Varun Mittal², Venkataraman Palabindala³, Shradha Ahuja³ and Vikas Majithia^1,4, ¹Division of Rheumatology, University of Mississippi, Jackson, MS, ²Division of Hematology and Oncology, Albert Einstein Healthcare Network, Philadelphia, PA, ³Division of Hospital Medicine, University of Mississippi, Jackson, MS, ⁴Jackson VA Medical Center and University of Mississippi, Jackson, MS
Background/Purpose: Fertility is reduced in patients with Rheumatoid Arthritis (RA) due to unknown cause. Few studies mostly involving single center cohorts have addressed pregnancy outcomes…
Abstract Number: 1391 • 2017 ACR/ARHP Annual Meeting
Ultrasound Response to Tocilizumab in Surgically Replaced Joints and Surgically Operated Joint Areas of Rheumatoid Arthritis Patients
Evan Choate¹, Gurjit S. Kaeley², Jenny Brook³, John Fitzgerald⁴, David Elashoff⁵ and Veena K. Ranganath⁶, ¹David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, ²Rheumatology, University of Florida College of Medicine, Jacksonville, Jacksonville, FL, ³Medicine, David Geffen School of Medicine, UCLA, Los Angeles, CA, ⁴David Geffen School of Medicine, Division of Rheumatology, Department of Internal Medicine, University of California, Los Angeles, Los Angeles, CA, ⁵David Geffen School of Medicine,, University of California, Los Angeles, Los Angeles, CA, ⁶Medicine/Rheumatology, University of California, Los Angeles, Los Angeles, CA
Background/Purpose: Rheumatoid Arthritis (RA) disease activity outcomes are used for treatment decisions (ie. DAS28-ESR). Surgically operated joints (SOJ) are assumed not to respond to therapy…
Abstract Number: 1392 • 2017 ACR/ARHP Annual Meeting
Effect Size Comparison of Ultrasound Measures in Rheumatoid Arthritis
Veena K. Ranganath¹, David Elashoff², Jenny Brook³, Ami Ben-Artzi⁴, Geraldine Navarro⁵, Lynnette Avedikian-Tatosyan⁶, George Karpouzas⁷, William Martin⁵, Tanaz A. Kermani⁵, Soo Choi⁵ and Gurjit S. Kaeley⁸, ¹Medicine/Rheumatology, University of California, Los Angeles, Los Angeles, CA, ²David Geffen School of Medicine,, University of California, Los Angeles, Los Angeles, CA, ³Medicine, David Geffen School of Medicine, UCLA, Los Angeles, CA, ⁴Medicine, Cedars, Beverly Hills, CA, ⁵Medicine, Division of Rheumatology, David Geffen School of Medicine, UCLA, Los Angeles, CA, ⁶Healthcare Partners, Los Angeles, CA, ⁷Division of Rheumatology, Harbor-UCLA Medical Center, Torrance, CA, ⁸Rheumatology, University of Florida College of Medicine, Jacksonville, Jacksonville, FL
Background/Purpose: Currently there are several outcome metrics used for the assessment and quantification of musculoskeletal (MSK) ultrasound inflammatory burden in rheumatoid arthritis (RA). This study…
Abstract Number: 1543 • 2017 ACR/ARHP Annual Meeting
Real-World Effectiveness of TNF Inhibition in Spondyloarthritis. Data from a Large Nationwide Prospective Cohort – the British Society for Rheumatology Biologics Register for Ankylosing Spondylitis
Gareth T. Jones¹, Andrew Keat², Ejaz Pathan³ and Gary J. Macfarlane¹, ¹Epidemiology Group, School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Aberdeen, United Kingdom, ²Rheumatology., Northwick Park Hospital, London, United Kingdom, ³Department of Rheumatology, Aberdeen Royal Infirmary, Aberdeen, United Kingdom
Background/Purpose: TNF inhibition has revolutionised the treatment of axial spondyloarthritis (AxSpA). Much of what we know about the use of these drugs comes from randomised…
Abstract Number: 1754 • 2017 ACR/ARHP Annual Meeting
Childhood- Vs. Adult-Onset ANCA-Associated Vasculitides: A Nested, Matched Case–Control Study from the French Vasculitis Study Group Registry
Michele Iudici¹, Christian Pagnoux², Pierre Quartier³, Mathias Büchler⁴, Ramiro Cevallos⁵, Pascal Cohen⁶, Claire de Moreuil⁷, Philippe Guilpain⁸, Alain Le Quellec⁸, Jacques Serratrice⁹, Benjamin Terrier⁶, Claire Le Jeunne⁶, Loïc Guillevin¹, Luc Mouthon¹⁰ and Xavier Puéchal for the French Vasculitis Study Group¹, ¹National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, ²Mount Sinai Hospital, Toronto, ON, Canada, ³Necker-Enfants Malades Hospital, Paris, France, ⁴Tours, Tours, France, ⁵Strasbourg, Strasbourg, France, ⁶Service de Médecine Interne, Hôpital Cochin, Centre de référence national pour les maladies systémiques autoimmunes rares d’Ile de France, DHU Authors, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France, Paris, France, ⁷CHU de Brest, Brest, France, ⁸Montpellier, Montpellier, France, ⁹Marseille, Marseille, France, ¹⁰Service de Médecine Interne, Hôpital Cochin, Centre de référence national pour les maladies systémiques autoimmunes rares d’Ile de France, DHU Authors, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France ;Université Paris Descartes Sorbonne Paris, Paris, France
Background/Purpose: ANCA-associated vasculitides (AAVs) are potentially life-threatening diseases rarely observed in childhood. Whether AAVs in children (cAAVs) differ from adult-onset AAVs (aAAVs) is still not…
Abstract Number: 1801 • 2017 ACR/ARHP Annual Meeting
Quantifying Clinical and Economic Outcomes Associated with Chronic Corticosteroid Exposure in a US Population
J. Bradford Rice¹, Alan White¹, Andrea Lopez¹, Aneesha Wagh¹, Yimin Qin², Ghaith Mitri², Laura Bartels-Peculis², Gosia Ciepielewska² and Winnie Nelson³, ¹Analysis Group, Inc., Boston, MA, ²Mallinckrodt Pharmaceuticals, Hampton, NJ, ³Health Economics and Outcomes Research, Mallinckrodt Pharmaceuticals, Hampton, NJ
Background/Purpose: Corticosteroids (CS) are commonly used for rheumatologic conditions, and known to cause systemic adverse events (AEs), particularly when used at high doses for prolonged…
Abstract Number: 907 • 2016 ACR/ARHP Annual Meeting
Rituximab in Patients with Takayasu Arteritis: A Single Center Experience on Five Patients
Giulia Pazzola¹, Francesco Muratore¹, Luigi Boiardi², Mariagazia Catanoso¹, Alessandra Soriano³, Pierluigi Macchioni¹, Lucia Spaggiari⁴, Massimiliano Casali⁵, Nicolò Pipitone¹, Niccolò Possemato⁶ and Carlo Salvarani¹, ¹Rheumatology Unit, Arcispedale S Maria Nuova, IRCCS, Reggio Emilia, Italy, ²Rheumatology Unit, Arcispedale S.Maria Nuova, IRCCS, Reggio Emilia, Italy, ³Rheumatology Unti, Arcispedale S Maria Nuova, IRCCS, Reggio Emilia, Italy, ⁴Radiology, Arcispedale S Maria Nuova, IRCCS, Reggio Emilia, Italy, ⁵Nuclear Medicine, Arcispedale S Maria Nuova, IRCCS, Reggio Emilia, Italy, ⁶Rheumatology Service, Arcispedale S Maria Nuova, IRCCS, Reggio Emilia, Italy
Background/Purpose: Takayasu arteritis (TAK) is a large vessel vasculitis involving the aorta and its major branches in patients younger than 40 years. Glucocorticoids (GCs) are…

« Previous Page
1
…
3
4
5
6
7
…
10
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].